You might associate autoimmune conditions with symptoms like skin disease, chronic pain, and fatigue. A less-discussed ...

Incidences of malignant neoplasms were low and stable with long-term ixekizumab treatment for people with psoriatic disease ...

Immune checkpoint inhibitors have changed the future of cancer care. These powerful treatments use the body’s own immune ...

Some medicines used for heart problems, like beta-blockers, ACE inhibitors, and calcium channel blockers, have been known to ...

Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.

Nearly nine million people in the U.S. have an inflammatory skin condition called plaque psoriasis. We're raising awareness ...

Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...

Lady T is joined by Dr. Mona Gohara, Medical Dermatologist and Associate Clinical Professor at the Department of Dermatology ...

This segment is sponsored by Arcutis Biotherapeutics.Nearly 9 million people in the U.S. have an inflammatory skin condition ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

For patients with psoriasis and Type 2 diabetes, the risk of developing chronic kidney disease (CKD) continued to rise ...